Search
Search
About
Log in
Join
Experiences with
Antagon
Posts
Communities
11,465 public posts
Filter results
Next steps
See my bio for a more complete history. Most recent psma pet scan demonstrated a couple of new spots in my hip and vertebra along with some old ones that are still smoldering. Psa is undetectable. Does this mean i am castrate resistant? Doc wants to send me to Turkey for Actinium 225. Has anybody received
See my bio for a more complete history. Most recent psma pet scan demonstrated a couple of new spots in my hip and vertebra along with some old ones that are still smoldering. Psa is undetectable. Does this mean i am castrate resistant? Doc wants to send me to Turkey for Actinium 225. Has anybody received
Irishman77
in
Advanced Prostate Cancer
7 days ago
Not impressed with Oncologist
After Prof. Peter Hoskin team consultant visit today Sep 20. 24, Leuprolide injection and bicalutamide were recommended for 6 months before 20 IMRT sessions somewhere in Jan 25, continuing with ADT for up to 2-3 years, but needs monitoring and adjusted accordinglyAfter that, brachy boost was recommended
After Prof. Peter Hoskin team consultant visit today Sep 20. 24, Leuprolide injection and bicalutamide were recommended for 6 months before 20 IMRT sessions somewhere in Jan 25, continuing with ADT for up to 2-3 years, but needs monitoring and adjusted accordinglyAfter that, brachy boost was recommended
Hotoneii
in
Advanced Prostate Cancer
7 days ago
Metastatic Prostate Cancer Resisting to Treatments
My dad (55) is diagnosed with metastatic prostate cancer that spread to his bones (mainly pelvic and ribs). He was put on Lupron, Docetaxel and Nubeqa. He made improvements in the first 4 months. PSA dropped to almost 0. However, once he started radiation and completed that, his conditions were getting
My dad (55) is diagnosed with metastatic prostate cancer that spread to his bones (mainly pelvic and ribs). He was put on Lupron, Docetaxel and Nubeqa. He made improvements in the first 4 months. PSA dropped to almost 0. However, once he started radiation and completed that, his conditions were getting
Aliannado
in
Advanced Prostate Cancer
7 days ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Just met my MO - was surprised he was a presenter at ESMO
Just met my MO. I was surprised to know he had attended ESMO and had presented something , though on breast cancer. Regarding dad’s results , he was happy with the fall In psa and ADT but said he was not comfortable that the T had risen from 26 to 41 in 2 months. Has said to do a repeat T
Just met my MO. I was surprised to know he had attended ESMO and had presented something , though on breast cancer. Regarding dad’s results , he was happy with the fall In psa and ADT but said he was not comfortable that the T had risen from 26 to 41 in 2 months. Has said to do a repeat T
Tinkudi
in
Advanced Prostate Cancer
8 days ago
PSMA pet scan results
Just had my scan on 9/17/24, prior to my scan my PSA was 0.80. I'll be speaking with my MO on 9/23. Any feedback would be helpful. Thanks EXAM DESCRIPTION: 18F-piflufolastat (PYLARIFY) PSMA targeted PET/CT COMPARISON: PET PSMA dated November 7, 2023 INDICATION: History of prostate cancer status
Just had my scan on 9/17/24, prior to my scan my PSA was 0.80. I'll be speaking with my MO on 9/23. Any feedback would be helpful. Thanks EXAM DESCRIPTION: 18F-piflufolastat (PYLARIFY) PSMA targeted PET/CT COMPARISON: PET PSMA dated November 7, 2023 INDICATION: History of prostate cancer status
Rfs1975
in
Advanced Prostate Cancer
8 days ago
PSA acting very weird
Recurrent prostate cancer after RP in 2018...though seemingly not metastatic...yet. Haven't done treatment. My story is in the profile and bio. Anyway, PSA got as high as the 9's earlier this year...then fell to 7.7 in July...and now in September registers 3.4. No idea what's happening or why.
Recurrent prostate cancer after RP in 2018...though seemingly not metastatic...yet. Haven't done treatment. My story is in the profile and bio. Anyway, PSA got as high as the 9's earlier this year...then fell to 7.7 in July...and now in September registers 3.4. No idea what's happening or why.
Nittany
in
Advanced Prostate Cancer
8 days ago
If PSA decreases in MHsPC but ALP increases , is one still castrate sensitive ?
I know that PSA decreasing or remaining steady while on hormone therapy means one is hormone sensitive but if PSA decreases but ALP increases , does that still mean one is hormone sensitive ?
I know that PSA decreasing or remaining steady while on hormone therapy means one is hormone sensitive but if PSA decreases but ALP increases , does that still mean one is hormone sensitive ?
Tinkudi
in
Advanced Prostate Cancer
9 days ago
Ok to do brisk walking before doing psa test ?
Is it ok to do brisk walking just before doing a PSA test. I know One should avoid cycling for a couple of days.
Is it ok to do brisk walking just before doing a PSA test. I know One should avoid cycling for a couple of days.
Tinkudi
in
Advanced Prostate Cancer
9 days ago
Step 2 - mpMRI done, results not good, I'm scared now
Hi all, I've been enjoying following many of your stories and it has helped me prepare for this journey. Thanks to everyone who graciously shares and responds here. My original post and bio tell my story, but I have to add this new information from my mpMRI this morning. Here it is: IMPRESSION:
Hi all, I've been enjoying following many of your stories and it has helped me prepare for this journey. Thanks to everyone who graciously shares and responds here. My original post and bio tell my story, but I have to add this new information from my mpMRI this morning. Here it is: IMPRESSION:
RazorSaw
in
Advanced Prostate Cancer
9 days ago
3 months post ADT ending checkup
Just completed my checkup after ending ADT in May. My doctor was looking to schedule a PSMA scan to build a baseline. Since I was diagnosed Gleason 9 there is a chance that cancer could reoccur without expressing PSA. ---- well my oncologist talked directly with the insurance advisors (I consulted a
Just completed my checkup after ending ADT in May. My doctor was looking to schedule a PSMA scan to build a baseline. Since I was diagnosed Gleason 9 there is a chance that cancer could reoccur without expressing PSA. ---- well my oncologist talked directly with the insurance advisors (I consulted a
chefjlu
in
Advanced Prostate Cancer
9 days ago
Started treatments in August 2024 and wondered about PSA numbers?
Started treatments in August 2024 and am monitored every two weeks due to Potassium level always going up. Remedied with a bag of fluids to help with any dehydration. Was wondering from the lab work if a drop in the PSA numbers means anything significant? Number at start was 52.4 and now at 22.4 after
Started treatments in August 2024 and am monitored every two weeks due to Potassium level always going up. Remedied with a bag of fluids to help with any dehydration. Was wondering from the lab work if a drop in the PSA numbers means anything significant? Number at start was 52.4 and now at 22.4 after
PARKER3237
in
Advanced Prostate Cancer
10 days ago
Nonmetastatic castrate resistant prostate cancer
I have been on hormone therapy for 10 years with stage 3 non-metastatic prostate cancer. Now I am very close to doubling the PSA < 10 months. Question. What kind of therapy should I expect when I reach a non-metastatic castrate-resistant form?
I have been on hormone therapy for 10 years with stage 3 non-metastatic prostate cancer. Now I am very close to doubling the PSA < 10 months. Question. What kind of therapy should I expect when I reach a non-metastatic castrate-resistant form?
Varsin
in
Advanced Prostate Cancer
10 days ago
ESMO 2024: Xaluritamig (AMG 509), a STEAP1 x CD3 XmAb 2+1 immune therapy for Metastatic CRPC: initial results of Phase 1
Xaluritamig, a novel bispecific T-cell engager targeting STEAP1, in patients with metastatic castration-resistant prostate cancer (mCRPC). STEAP1 is a cell surface antigen highly expressed in prostate cancer and is associated with poor prognosis. Xaluritamig is designed to redirect T-cells to kill
Xaluritamig, a novel bispecific T-cell engager targeting STEAP1, in patients with metastatic castration-resistant prostate cancer (mCRPC). STEAP1 is a cell surface antigen highly expressed in prostate cancer and is associated with poor prognosis. Xaluritamig is designed to redirect T-cells to kill
Maxone73
in
Advanced Prostate Cancer
10 days ago
Need Help NOW
Hello fellow fighters! My husband has recently finished 6 rounds of Pluvicto and his PSMA PET scan has shown considerable spread throughout his bones. His PSA continued to rise during the Pluvicto treatment and the RO convinced us that it was probably just debris field from the dying bone lesions. It
Hello fellow fighters! My husband has recently finished 6 rounds of Pluvicto and his PSMA PET scan has shown considerable spread throughout his bones. His PSA continued to rise during the Pluvicto treatment and the RO convinced us that it was probably just debris field from the dying bone lesions. It
Fighting4u
in
Advanced Prostate Cancer
10 days ago
ESMO 2024: Opevesostat (MK-5684/ODM-208) in metastatic CRPC updated CYPIDES phase 2 results
Not bad but you need a mutation! The trial enrolled 134 heavily pre-treated mCRPC patients who had progressed after at least one novel hormonal agent and one taxane chemotherapy. Among these patients, 66 had activating mutations in the androgen receptor ligand-binding domain (AR-LBD), known to confer
Not bad but you need a mutation! The trial enrolled 134 heavily pre-treated mCRPC patients who had progressed after at least one novel hormonal agent and one taxane chemotherapy. Among these patients, 66 had activating mutations in the androgen receptor ligand-binding domain (AR-LBD), known to confer
Maxone73
in
Advanced Prostate Cancer
10 days ago
ESMO 2024: phase 1/2 trial of oral masofaniten (EPI-7386) plus Enzalutamide compared to Enzalutamide alone in men with mCRPC
This looks promising. The trial enrolled 18 patients who were on androgen deprivation therapy but had not received prior AR pathway inhibitors; some had received chemotherapy in the hormone-sensitive setting. Patients were treated with escalating doses of Masofaniten (EPI-7386), up to 600 mg twice daily
This looks promising. The trial enrolled 18 patients who were on androgen deprivation therapy but had not received prior AR pathway inhibitors; some had received chemotherapy in the hormone-sensitive setting. Patients were treated with escalating doses of Masofaniten (EPI-7386), up to 600 mg twice daily
Maxone73
in
Advanced Prostate Cancer
10 days ago
ESMO 2024: TAMARACK, a randomized phase 2 trial of the B7-H3 targeting ADC Vobramitamab for metastatic CRPC
My sensation is that it is too early to say ho well it works, but SE look pretty harsh! The trial enrolled 181 men with mCRPC who had previously received one androgen receptor pathway inhibitor. Participants were randomized to receive vobramitamab at either 2.0 mg/kg or 2.7 mg/kg every four weeks. The
My sensation is that it is too early to say ho well it works, but SE look pretty harsh! The trial enrolled 181 men with mCRPC who had previously received one androgen receptor pathway inhibitor. Participants were randomized to receive vobramitamab at either 2.0 mg/kg or 2.7 mg/kg every four weeks. The
Maxone73
in
Advanced Prostate Cancer
10 days ago
ESMO 2024 - UpFrontPSMA: randomized study of sequential 177Lu-PSMA-617 and Docetaxel vs Docetaxel in metastatic prostate cancer
Data about overall survival seems immature to me, it seems like there is a slight advantage for the sequential therapy, not very significant, but both arms at 36 months are far away from having reached the median. So I think we have to wait for that parameter. The study enrolled 130 patients with de
Data about overall survival seems immature to me, it seems like there is a slight advantage for the sequential therapy, not very significant, but both arms at 36 months are far away from having reached the median. So I think we have to wait for that parameter. The study enrolled 130 patients with de
Maxone73
in
Advanced Prostate Cancer
10 days ago
ESMO 2024: BMS-986365 in heavily pretreated patients with mCRPC
Ok, I am not so impressed with this new molecule, but here it is. BMS-986365 is designed to inhibit androgen receptor (AR) activity through a dual mechanism of degrading the receptor and blocking its function, aiming to overcome resistance to standard AR pathway inhibitors like enzalutamide and abiraterone
Ok, I am not so impressed with this new molecule, but here it is. BMS-986365 is designed to inhibit androgen receptor (AR) activity through a dual mechanism of degrading the receptor and blocking its function, aiming to overcome resistance to standard AR pathway inhibitors like enzalutamide and abiraterone
Maxone73
in
Advanced Prostate Cancer
10 days ago
ESMO 2024: darolutamide plus ADT in Patients with mHSPC from ARANOTE Trial
My take here is: patients receiving darolutamide and ADT had a 46% reduction in the risk of disease progression or death compared to those on ADT alone (hazard ratio [HR] 0.54). Secondary endpoints also favored the darolutamide group, including delays in the time to castration-resistant prostate cancer
My take here is: patients receiving darolutamide and ADT had a 46% reduction in the risk of disease progression or death compared to those on ADT alone (hazard ratio [HR] 0.54). Secondary endpoints also favored the darolutamide group, including delays in the time to castration-resistant prostate cancer
Maxone73
in
Advanced Prostate Cancer
10 days ago
1
2
3
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
9105 results
Prostate Cancer Network
1103 results
Fight Prostate Cancer
262 results
View top 10 communities
Sort by
Most Relevant
Newest